Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance and Clinical Trials Arena. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 49d ago.
Quick answers
Why is "Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pa" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? Yahoo Finance · 83d ago
- Moderna highlights expanding mRNA platform at Science Day Clinical Trials Arena · 83d ago
Topics
Related trends
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Dow Jones futures face pressure as anticipation of a Federal Reserve rate hike coincides with rising oil prices and yields.
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
What to know about the new mRNA flu vaccine
Health coverage highlights FDA approval of Moderna's new mRNA flu vaccine and emerging studies on broader antibody responses.
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.